Documentation ephemerisx.com

Drug and company pages

Each drug and company on the Ephemeris has its own page, which opens the map zoomed onto it with an information card.

Last updated September 29, 2026

Every item on the Ephemeris has its own address. The page opens the full map, already zoomed onto that item, with an information card at the top of the list. The rest of the map is one Fit the whole map away.

Addresses#

  • Drugs and FDA records: /ephemeris/fda/<name>/, for example /ephemeris/fda/leqembi/ or /ephemeris/fda/advisory-committee-record/.
  • Companies: /ephemeris/sec/<company>/, for example /ephemeris/sec/aldeyra-therapeutics/.

The full list is in the URL directory.

Drug pages#

The Leqembi page on the FDA Ephemeris: an information card above the list, and the map zoomed onto the Leqembi cluster.
The Leqembi page, /ephemeris/fda/leqembi/.

The information card shows, from top to bottom:

  1. A back link, ← The FDA Ephemeris: the whole map.
  2. The drug's name and generic name.
  3. Where it stands, in one sentence. For example:
    • “In the graph: all N documents (N pages).”
    • “In the graph: 13 of 24 documents (939 of 1,090 pages); the rest are queued.”
    • “Queued: N FDA documents (N pages) are in the system, waiting to be read into the graph.”
    • “Listed: the approval is known from Drugs@FDA; its review documents are not yet in the Ephemeris.”
  4. Facts: Application, Sponsor, Drug class, First approved and, for listed drugs, Drugs@FDA status.
  5. FDA decisions, for drugs with decisions in the record: each dated, with its pathway (for example Accelerated approval, Traditional approval, Complete response), linked to its entry on the Alzheimer's record.
  6. Related drugs in the same class, linked to their pages.
  7. Fine print: “From FDA documents. Not medical advice.”

A listed-only drug arrives with its dot selected, and links to its application on Drugs@FDA.

Company pages#

The Aldeyra Therapeutics page on the SEC Ephemeris.
A company page on the SEC Ephemeris.

A company's card has the same layout, with SEC facts: Application, Ticker, Product, Disease area, Response path, the dates of each Complete Response Letter, and Where it stands. Its fine print reads “From FDA letters and SEC filings. Not investment or medical advice.”